Table 3.
Management of patients during ICU stay.
| No cancer (n=315) | Cancer patients (n=105) | Hematological maligancies (n=51) | Solid tumors (n=54) | |
|---|---|---|---|---|
| Time from ICU admission to oro-tracheal intubation, days | 0 (0 - 0) | 0 (0 - 1) | 0 (0 - 3) | 0 (0 - 1) |
| Oro-tracheal intubation, hours | 360 (206 - 610) | 360 (205 - 671) | 504 (219 - 864) | 306 (184 - 420) |
| Oxygen delivery method at ICU admission | ||||
| Nasal cannulae | 27 (8·6%) | 9 (8·6%) | 4 (7·8%) | 5 (9·3%) |
| Non-rebreather mask | 51 (16·2%) | 20 (19·0%) | 13 (25·5%) | 7 (13·0%) |
| Non-invasive ventilation | 14 (4·5%) | 2 (1·9%) | 0 (0%) | 2 (3·7%) |
| High-flow nasa-oxygen | 120 (38·2%) | 39 (37·1%) | 17 (33·3%) | 22 (40·7%) |
| Invasive machanical ventilation | 102 (32·5%) | 35 (33·3%) | 17 (33·3%) | 18 (33·3%) |
| Lower PaO2/FiO2 ratio during ICU stay | 89 (65 - 130) | 72 (57 - 105) | 68 (57 - 100) | 83 (57 - 110) |
| Prone positionning | 152 (48·4%) | 66 (62·9%) | 36 (70·6%) | 30 (55·6%) |
| Norepinephrine | 157 (50·2%) | 73 (69·5%) | 38 (74·5%) | 35 (64·8%) |
| Extra-corporeal membrane oxygenation | 7 (2·2%) | 4 (3·8%) | 2 (3·9%) | 2 (3·7%) |
| Antimicrobial treatment | 256 (81·3%) | 94 (89·5%) | 49 (96·1%) | 45 (83·3%) |
| Specific anti-SARS-CoV-2 treatment | 230 (73·0%) | 77 (73·3%) | 39 (76·5%) | 38 (70·4%) |
| Corticosteroids | 189 (60·0%) | 61 (58·1%) | 29 (56·9%) | 32 (59·3%) |
| Remdesivir | 3 (1·0%) | 2 (1·9%) | 1 (2·0%) | 1 (1·9%) |
| Ritonavir/Lopinavir | 9 (2·9%) | 2 (1·9%) | 1 (2·0%) | 1 (1·9%) |
| Hydroxychloroquin | 12 (3·8%) | 7 (6·7%) | 5 (9·8%) | 2 (3·7%) |
| Hydroxychloroquin + azithromycin | 19 (6·0%) | 5 (4·8%) | 4 (7·8%) | 1 (1·9%) |
| Plasma therapy | 2 (0·6%) | 2 (1·9%) | 2 (3·9%) | 0 (0%) |
| Polyvalent immunoglobulin | 6 (1·9%) | 2 (1·9%) | 0 (0%) | 2 (3·7%) |